Sam Sater, MD
Medical Oncology · Port Saint Lucie, FLNPI 1619256377
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,110 of the $6,696 with a category attached, or 61.4%. Daiichi Sankyo Inc. accounts for 78.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $5,551 and has fallen 97.5% since, to $137 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 30 payments — averaging $223.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$5K
- AstraZeneca$1K
- Sobi, Inc$96
- Novo Nordisk$43
- Incyte Corporation$35
- Novartis$33
- plus $258 from 12 others
Across 6 payments — averaging $44,689 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$187K
- Astrazeneca UK Limited$49K
- AstraZeneca$33K
What the payments were for
- Consulting fees$4,11061%
- Speaking & faculty fees$95014%
- Travel & lodging$76211%
- Food & beverage$86113%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 8 | $5,229 |
| AstraZeneca | 4 | $1,002 |
| Sobi, Inc | 1 | $96 |
| Novo Nordisk | 1 | $43 |
| Incyte Corporation | 2 | $35 |
| Novartis | 2 | $33 |
| Sanofi | 1 | $32 |
| Merck | 1 | $28 |
| Geron Corporation | 1 | $26 |
| Gilead | 1 | $25 |
| Lilly USA, LLC | 1 | $21 |
| Foundation Medicine, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Tempus AI, Inc | 1 | $19 |
| Beigene USA, Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,696 in reported general payments places this provider in the 40th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 33 | $614 |
| Letrozole | 11 | $190 |
| Prednisone | 14 | $39 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Port Saint Lucie
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.